Good morning, ladies and gentlemen, and welcome to the Teleflex fourth quarter 2023 earnings conference call. At this time, all participants have been placed in a listen-only mode. At the end of the company's prepared remarks, we will conduct a question-and-answer session. Please note that this conference call is being recorded and will be available on the company's website for replay shortly. Now I will turn the call over to Mr. Lawrence Keusch, Vice President of Investor Relations and Strategy Development. Good morning, everyone, and welcome to the Teleflex Incorporated fourth quarter 2023 earnings conference call. The press release and slides to accompany this call are available on our website at teleflex.com. As a reminder, a replay will be available on our website, and for those wishing to access the replay, you can refer to our press release from this morning for details. Participating on today's call are Liam Kelly, Chairman, President, and Chief Executive Officer, and Thomas Powell, Executive Vice President and Chief Financial Officer. Liam and Tom will provide prepared remarks, and then we will open the call to Q&A. Before we begin, I'd like to remind you that some of the matters discussed in the conference call will contain forward-looking statements regarding future events as outlined in the slides posted to the Investor Relations section of the Teleflex website. We wish to caution you that such statements are, in fact, forward-looking in nature and are subject to risks and uncertainties, and actual events or results may differ materially. The factors that could cause actual results or events to differ materially include but are not limited to factors referenced in our press release today, as well as our filings with the SEC, including our Form 10-K, which can be accessed on our website. Now I'll turn the call over to Liam for his remarks. Thank you, Larry, and good morning, everyone. On this morning's call, we will discuss the fourth quarter results, provide some commercial updates, and introduce our financial guidance for 2024. We had a solid finish to 2023 as momentum seen through the year continued into the fourth quarter. For the quarter, Teleflex revenues were $773.9 million, a year-over-year increase of 2.1%, and an increase of 0.7% on a constant currency basis. As a reminder to investors, there were five fewer shipping days year-over-year in the fourth quarter. The shipping day impact in the quarter was an estimated $57 million, or approximately a 7.4 percentage point reduction in constant currency growth year-over-year. When adjusting for the shipping day impact, the implied constant currency growth was 8.1% year-over-year. Fourth quarter adjusted earnings per share was $3.38, a 4% decrease year-over-year. During the quarter, utilization continued to return towards normal seasonality. From a macro perspective, we witnessed a stable to improving environment for material inflation and supply chain. These dynamics generally track to our expectations for the full year. For the full year 2023, we had a strong performance with revenues reaching $2.975 billion, which represents 6.5% constant currency growth year-over-year, while adjusted earnings per share was $13.52. As we look to 2024, we anticipate a stable procedure environment with seasonality in line with pre-pandemic levels. Although the Teleflex portfolio is not likely to benefit from pent-up demand due to the focus on critical care procedures, we would anticipate that staffing will continue to see improvements during the year. Supply chain dynamics largely stabilized through 2023, and we expect to see continued improvements in 2024. Teleflex has broad global manufacturing capabilities, and we continue to assess vertical integration opportunities to gain further control of our supply chain. Turning to inflation. There were elements of improvement during 2023, including seafreight and raw materials. For 2024, we are assuming some further disinflation, but note that costs remain somewhat elevated relative to historic levels and are above 2023. Now let's turn to a deeper dive into our fourth quarter revenue results. I will begin with a review of our geographic segment revenues for the fourth quarter. All growth rates that I refer to are on a constant currency basis and reflect the negative impact of five fewer shipping days year-over-year unless otherwise noted. Americas revenues were $450.6 million, a 1.9% decrease year-over-year driven by surgical and vascular, and reflective of the five fewer shipping days in the quarter. In particular, we saw year-over-year growth in our interventional anesthesia and interventional urology businesses despite the fewer shipping days in the quarter. EMEA revenues of $152.4 million decreased 2.7% year-over-year driven by anesthesia and surgical, and reflective of the impact of the fewer shipping days. Urology products, interventional, and vascular businesses generated the highest shipping days adjusted growth in the quarter. Turning to Asia. Revenues were $88.3 million, increasing 12.6% year-over-year. Revenue growth was broad-based across the region, with strong double-digit increases in Korea, India, and China. The performance in the quarter was driven by strong commercial execution and solid underlying demand. Let's now move to a discussion on our fourth quarter revenue by global product category. Commentary on global product category growth for the fourth quarter will also be on a year-over-year constant currency basis and reflects the impact of the five fewer shipping days. On a shipping days adjusted basis, the sequential growth in the fourth quarter trended in line with our expectations, with vascular and anesthesia growth rates improving while interventional and surgical slowed. Starting with vascular access. Revenue decreased 1.2% to $186.7 million. Along with the fewer shipping days, the year-over-year growth also reflected the impact of the previously announced Endurance catheter recall. The quarter was led by year-over-year growth for EZ-IO and other access despite headwinds from the fewer shipping days. Of note, we achieved double-digit growth in our underlying PICC business when excluding the negative impact of the Endurance recall. We continue to see opportunities for share gains in the peripheral access market, and our new product initiatives will help play a role. During the quarter, we continue to execute on our launch activities for our next-generation navigation device and new PICC stylet. Moving to interventional. Revenue was $135.6 million, up 7.2% year-over-year. Despite the impact of the fewer selling days, we demonstrated solid growth, which underscores our positive momentum as we continue to make good progress with our growth drivers. Turning to anesthesia. Revenue declined 3.4% year-over-year to $98.2 million. Among our larger product categories, hemostatic products performed well in the quarter with strong double-digit growth, partially offset by declines in atomization and ET tubes as we recover from the recall which occurred earlier in 2023. In our surgical business, revenue was $109.6 million, down 2% year-over-year against a tough comparison. Our underlying trends in our core surgical franchise continue to be solid, including our ligation portfolio. For 2023, Titan generated revenues in excess of $12 million. For interventional urology, revenue was $93 million, representing an increase of 4.2%. Starting with Palette, which we acquired in October 2023, revenues in the fourth quarter were modestly better than expectations without performance of Barrigel. For UroLift, the office remains a challenge as we continue our efforts to stabilize this site of service. In the international markets, UroLift revenue saw healthy growth in Japan, while in China, our initial launch activities remain on plan with a focus on training surgeons and gaining reimbursement. OEM had another solid quarter, with revenues increasing 10.9% year-over-year to $82.6 million. A strength in the quarter was broad-based across our portfolio, with all product categories recording year-over-year growth, including continued strength in microcatheters. Fourth quarter other revenue declined 10.2% to $68.2 million year-over-year. As previously disclosed, fourth quarter other revenues reflects the early December 2023 exit of the MSA by Medline and accounted for the majority of the year-over-year revenue decline. That completes my comments on the fourth quarter revenue performance. Turning to some commercial and clinical updates. Following the acquisition of Palette Life Sciences on October 10th, 2023, I am pleased to report that the integration is tracking to our expectations. We have completed initial cross-functional product sales training for selected members of our legacy UroLift sales force, and our dual bag reps are now interacting with clinicians in the field. Our focus remains on expanding the use of rectal spacing in the treatment of prostate cancer, and we are engaging with urologists and radiation oncologists. Barrigel is a differentiated rectal spacer that is clinically proven to significantly reduce unwanted radiation exposure. Moving to UroLift. We continue to expand our foundation of clinical data that supports the use of UroLift as a safe and effective minimally invasive treatment for BPH. In November 2023, we highlighted a new peer-reviewed study in the Nature journal Prostate Cancer and Prostatic Diseases that reinforces the position of the UroLift system as the gold standard in minimally invasive surgical treatment for BPH. Results suggested that within one year of BPH surgery, one in 20 patients may require retreatment regardless of whether they receive a TURP, GreenLight Rezūm, or UroLift. Additionally, at one year, procedural complications requiring a return procedure in the outpatient setting were lowest following UroLift and highest following Rezūm. The average time to the first complication was the longest for UroLift. At five years, retreatment was lowest for TURP and statistically similar between GreenLight and UroLift. The retreatment rate for UroLift is comparable to published controlled trial rates, thereby underscoring the durability of the UroLift system. We continue to focus on supporting UroLift with clinical data and note that we have eight sponsored research abstracts that have been accepted for presentation at major urological meetings in 2024. Turning to an update related to our surgical business unit. We have completed the launch activities for the Gore Seamguard Bioabsorbable Staple Line reinforcement material to be used with the Titan stapler. The ability to offer synthetic buttressing material alongside the unique features of the Titan stapler should enable Teleflex to further address surgeon clinical needs and preferences in the sleeve gastrectomy market. Lastly, as we look into 2024, we will continue to advance our new product introductions with a number of launches across our business units. In our interventional business, we expect to receive FDA marketing clearance and launch the Ringer catheter in the second half of 2024. Ringer incorporates a unique balloon design that allows blood to flow through a vessel while the balloon is inflated. We will initially launch with a PTCA indication, but we have completed enrollment in a vessel perforation trial that will be utilized to seek FDA-label expansion. In our surgical business, we anticipate launching new ligation products, including an automated polymer clip applier, in the second half of 2024. We will also continue to refresh our laryngoscope families with a series of launches during the year. Our anesthesia business unit is also on track for new product launches, including updated technology in our EZ-IO business that would enable expansion of our user base, for which we expect FDA approval in 2024. We will provide more details upon launch. That completes my prepared remarks. Now I would like to turn the call over to Tom for a more detailed review of our fourth quarter financial results. Tom. Thanks, Liam, and good morning. Given the previous discussion of the company's revenue performance, I'll begin with margins. For the quarter, adjusted gross margin was 60.1%, a 10 basis point increase versus the prior year period. The year-over-year increase was primarily due to favorable price, benefits from cost improvement initiatives, lower logistics and distribution-related costs, and the Palette acquisition, partially offset by continued cost inflation and unfavorable fluctuations in foreign exchange rates. Adjusted operating margin was 26.3% in the fourth quarter. The 160 basis point year-over-year decrease was primarily driven by the inclusion of Palette Life Sciences operating expenses, employee-related expenses, and investments to grow the business, partially offset by the flow-through of the year-over-year increase in gross margin. Net interest expense totaled $22.5 million in the fourth quarter, an increase from $18.7 million in the prior year period. The year-over-year increase in net interest expense reflects higher interest rates versus the prior year and higher average debt outstanding utilized to fund the acquisition of Palette, partially offset by increased interest income. Our adjusted tax rate for the fourth quarter of 2023 was 11.6% compared to 13.6% in the prior year period. The year-over-year decrease in our adjusted tax rate is primarily due to an increase in tax deductions as a result of additional amortization of R&D costs, which, as a result of a U.S. tax law change, resulted in capitalization of such costs starting in 2022. At the bottom line, fourth quarter adjusted earnings per share was $3.38, a decrease of 4% versus prior year. The year-over-year decrease in EPS reflects dilution from the acquisition of Palette Life Sciences and the related incremental borrowings. Turning now to select balance sheet and cash flow highlights. Cash flow from operations for the 12 months was $511.7 million compared to $342.8 million in the prior year period. The $168.9 million increase was primarily attributable to lower tax payments, favorable changes in working capital, and favorable operating results. The favorable changes in working capital were primarily driven by lower inventory purchases stemming from the buildup of inventory in the prior year due to elevated global supply chain volatility. Moving to the balance sheet. At the end of the fourth quarter, our cash balance was $222.8 million as compared to $292 million as of the end of 2022. For the 12 months, the decrease in cash is primarily due to payments to fund the Palette acquisition, partially offset by net proceeds from borrowings and operating cash flow. Net leverage at quarter end was approximately 1.9 times. Inclusive of the acquisition of Palette Life Sciences, our financial position remains sound and continues to provide us flexibility to execute on our long-term capital allocation strategy. Turning now to financial guidance. Starting with a couple of discrete items for 2024. First, we continue to expect the Palette acquisition to be $0.35 diluted to the company's adjusted earnings per share in 2024. Beginning in fiscal year 2025, the transaction is expected to be increasingly accretive to adjusted EPS. Second, as previously disclosed, the manufacturing transition services agreement with Medline associated with our sale of certain respiratory assets concluded in December 2023. Of note, Teleflex generated $75.7 million in revenues from the MSA in 2023, which will not repeat in 2024. Moving to our outlook for 2024. We are expecting 2024 constant currency revenue growth of 3.75%-4.75%. The year-over-year growth includes the loss of the $75.7 million in MSA revenues, partly offset by the incremental revenues from Palette. Turning to foreign exchange. We assume approximately $5 million or 15 basis points headwind to revenue from foreign exchange translation in 2024. Our outlook for foreign exchange includes a euro to dollar exchange rate of approximately 1.08. Netting the loss of MSA revenues, the incremental Palette sales, and foreign exchange headwinds represents an approximately 100 basis point year-over-year headwind to growth in 2024. Considering the foreign exchange outlook, we expect reported revenue growth of 3.6%-4.6% in 2024, implying a dollar range of $3.082 billion-$3.111 billion. Turning to margins. We expect 2024 gross margin to be in the range of 60%-60.75%. Our gross margin guidance reflects the year-over-year positive impacts from the termination of the MSA, manufacturing efficiencies, price, and the Palette acquisition, partially offset by inflation and the impact of changes in foreign currency exchange rates. We expect operating margin to be in the range of 26.25%-26.75% for 2024. Our guidance reflects the flow-through of gross margin and the positive impact of restructuring, offset by the inclusion of operating expenses for Palette Life Sciences and investments to grow the business. Moving to items below the line. Net interest expense is expected to approximate $78 million for 2024. The majority of the year-over-year increase in our net interest expense outlook reflects the impact of borrowings associated with the Palette acquisition, partially offset by planned debt repayments during 2024. Our tax rate is expected to be approximately 12% for 2024, which reflects favorable mix offset by discrete items in 2023 that will not repeat in 2024, and the impact of Pillar 2 global minimum tax. We estimate the impact of Pillar 2 to add approximately 150 basis points to the 2024 tax rate. Turning to earnings. We expect 2024 adjusted earnings per share to be in the range of $13.55-$13.95. Our adjusted EPS outlook reflects $0.35 of dilution from the acquisition of Palette, $0.26 of dilution from the termination of the MSA, and a $0.23 headwind associated with the year-over-year increase in our tax rate, primarily due to the Pillar 2 minimum tax. Relative to foreign exchange, although there is a negligible impact on revenue, the headwind to earnings per share is approximately $0.24 year-over-year. Based on current foreign exchange rates, we expect roughly half of the headwind to EPS to fall into the first quarter of 2024. When adjusting for these items, including the negative impact of foreign exchange, the underlying adjusted constant currency EPS growth is approximately 7% at the low end of guidance and 10% at the high end of guidance. Although we do not provide quarterly guidance, for your modeling purposes, we expect reported revenues for the first quarter to be in the range of $725 million-$730 million, including a negligible foreign exchange impact year-over-year. That concludes my prepared remarks. I would now like to turn it back to Liam for closing commentary. Thanks, Tom. In closing, I will highlight our three key takeaways from the fourth quarter of 2023. First, we delivered on our financial commitments for 2023. For the year, constant currency revenues increased 6.5% and adjusted earnings per share were $13.52. Compared to our initial 2023 guidance, constant currency revenue growth exceeded our guidance, while adjusted earnings per share was at the high end of our range. Our execution remains strong. We are launching new products, and our margins remain healthy. Second, the fourth quarter performance and stable-to-improving macro environment provide the solid foundation for growth as we head into 2024. Third, we will continue to focus on our strategy to drive durable growth. We will invest in organic growth opportunities and drive innovation over time, expand our margins, and execute on our disciplined capital allocation strategy to enhance long-term value creation. The integration of Palette is progressing well, and we expect the acquisition to be a meaningful contributor to our growth in the coming years. That concludes my prepared remarks. Now I would like to turn the call back to the operator for Q&A. Thank you. If you'd like to ask a question, please press star one on your telephone keypad. If you're using a speakerphone, make sure your mute function is turned off to allow your signal to reach our equipment. We do ask that you limit yourself to one question and one follow-up. If you would like to ask additional questions, we invite you to add yourself to the queue again by pressing star 1. Our first question comes from a line of Patrick Wood with Morgan Stanley. Please go ahead. Good morning, and thanks for taking the questions. I guess the first one, Palette, we all talk a lot about Barrigel, understandably, as the bulk of the business, but you obviously acquired with that a number of other urology assets that are a little bit smaller. And that combined with, obviously, UroLift and Barrigel, you've got a bit of a platform that you're kind of building up on that side of things. So my question's essentially like, how much interest is there for you guys longer term in scaling up in that market overall, just given it's quite a fragmented industry and there's quite a lot of interest in different areas? Is that something that's kind of crossed your minds, or is it you're kind of now done with urology to your minds? UroLift in 2017. We knew the urology call point very well because of our surgical business. There isn't a radical prostatectomy done in the world that doesn't use one of our surgical products. We built on that with the Palette acquisition. The main product in there is the Barrigel for rectal spacing. It's performed beyond our expectations in the first quarter of ownership, and that momentum, we'll carry that on. We will integrate Palette before we do anything else in the urology space, but urology is definitely an area of interest to us, Patrick. In particular, men's health. There are areas within men's health that are open for disruption. There are some parts of men's health that haven't had innovation or new technologies in a number of years, similar to the fact that there had been no disruption to BPH until UroLift came onto the market. So we think there are areas for disruption within men's health, and it is an area of focus for us, probably not in the next six months, Patrick, to be fair, as we integrate Palette into Teleflex. But thereafter, our balance sheet, as you know, is in great shape, so we would see that as a definite area of expansion for Teleflex. Super interesting. Thank you. Then as a quick follow-up, you've obviously got a lot of product launches moving through 2024. You have things that are moving from diluted to accretive. The inflation environment's getting a little bit better. There's things that are moving considerably in your direction as we move through 2024. Is that environment part of what gives you confidence around the 2025 LRP, not to jump the shark, but is that big PICCture why you still feel very confident in that? Yeah. I feel really good about the LRP. If you start with the revenue, in our first year, we did 6.5%. Obviously, our guide this year is 3.75%-4.75%, but with 100 basis point headwind. So the underlying growth that we're expecting this year is 4.75%-5.75%, adjusting for those headwinds. And as we head into the second year of the LRP, I feel confident in our ability to deliver the current guidance, and that will be the springboard into next year, the final year of the LRP. For me, it's all about execution. I think we executed really well in 2023, and my goal is to continue to execute as we did in 2023 through 2024, at a minimum, each quarter achieving and hopefully beating our goals as we migrate through the year. Then on the margins, I think we're going to take a step up again this year in gross margins, and it'll be tougher for us to get to the our margin goal, in all transparency, and I think the investment community know that. We've had more inflation than we've thought, and we brought in a great asset in Palette, but that asset brought some OpEx. But we still think they're the right numbers for us, and we feel we have a path to get there. Our next question comes from a line of Jayson Bedford with Raymond James. Please go ahead. Good morning. Maybe just on gross margin, the fourth quarter was strong. I wanted to ask about the 2024 guide. You did, what, 59.5% in 2023. I thought the MSA adds 100 basis points, and then you have Palette. You have a bigger revenue base. So I guess my question is, is the gross margin headwind all on the FX side, or are there any new pressures that you're contemplating here? Well, to your point, we get a nice benefit in 2024 from both the acquisition of Palette and from the exit from the MSA. So those are both accretive to gross margin. What I would say is that we've got a number of headwinds. As Liam had mentioned, inflation is still higher than it had been pre-pandemic. And if you look at the total of our favorable pricing, savings from manufacturing cost improvements, savings from footprint programs, they're able to offset those inflationary pressures as well as some capitalized balances that are on the balance sheet and will roll out into the P&L in 2024. So those are kind of a wash. In addition to the inflation headwinds, we're also experiencing a modest adverse impact from foreign exchange. Okay. Thank you. Then just maybe to pile on the last line of questioning, on the urology selling effort, have you seen any selling synergies between Barrigel and UroLift, and can we assume that there's nothing baked into the guide? Jason, you can definitely assume there's nothing baked into the guide. I will tell you that for UroLift, we saw a modest improvement in Q4 versus Q3, so we're monitoring that pretty closely. We still expect $66 million-$68 million for Palette. We still expect interventional urology will deliver approximately 7.5% revenue growth at the midpoint. The low point of our guide assumes that it will grow just a little bit above 7%. The midpoint also assumes there's no improvement on UroLift from quarter three. The reason we use quarter three is the most recent quarter without a day's impact our seasonality. They have a tough comp in Q1 right out of the gate, but after that, I would expect that they would continue to show some improvement as we go through the year. But I think that the guidance, our entire guidance, I believe, is appropriately prudent, Jason. I think, as I said earlier, our goal is to execute against that as we go through the year. As a team, I think we feel really confident in our ability to deliver on all aspects of it. Our next question comes from a line of Shagun Singh with RBC Capital Markets. Please go ahead. Thank you so much for taking the question. I just wanted to touch on the 2024 guidance. You're calling for about 5%-6% growth adjusted for the one-time headwind tailwinds that you called out, and I believe delivering about 1.5 times EPS growth relative to sales growth. Why the conservatism, especially on the top line, given the strong exit in 2024 sorry, 2023, and then I have a follow-up. Thank you, Shagun. So look, we're really happy with where we landed at the end of 2023 in quarter four. If you adjust for the days, we delivered a robust 8.1% growth in the fourth quarter, and in the entire year, we delivered 6.5%. I will say, Shagun, that if you look at the low point of our guide this year at 3.75% and you add back that percent to get you to 4.75%, it's the exact same starting point at the low point as we had last year. I think that the guide is prudent. I think the guide sets us up so that we can execute as we go through the year, and I think that it allows us, as we go through the year as a company, to do what we did in 2023, and that has always been our goal. Now, there are a couple of moving pieces within the guide, Shagun, from the different business units. I would expect APAC, OEM, and IA and surgical to take a modest step back, surgical because they'll have anniversaried, the Titan acquisition. And then I would expect a modest step forward in growth rate for EMEA, interventional urology, vascular, and anesthesia. And I think that I feel, as I said, good about the way we've guided us, and I feel good about our ability to deliver it. Got it. Then just on M&A, Liam, can you provide us your updated thinking there, and especially how you're thinking about short-term P&L dilution relative to top-line accretive M&A and any interest in adjacencies? Thank you for taking the questions. Yeah, thank you. Well, I think, as I say always, the most important thing you need when you're doing M&A is firepower, and we have that. We're 1.9 times leveraged, which gives us lots of ability without raising our leverage too much. We are conscious of dilution. Our investors have given us feedback that in 2024, unfortunately, always doing the right thing by Teleflex, but two things hitting in the one year has caused a lot of dilution. And as Tom walked you through the bridge, our underlying earnings per share growth is really positive. But you obviously have the MSA, which is causing some dilution there, and also you have Palette causing some dilution in FX. And you add all of those up, and the midpoint of our growth is or the range of our growth is 7%-10% if you excluded those. So we are cognizant of that. We are out there in the marketplace looking at assets. Our M&A team is busy, and there are attractive assets in the marketplace that we believe would fit well within the Teleflex family, and we will continue to execute that with the thought to investor feedback on dilution. Our next question comes from a line of Matt Taylor with Jefferies. Please go ahead. Hey, good morning. This is Mike Sarcone from Matt. Thanks for taking my question. Just a first one on guidance, understanding that you provided Q1, which is helpful, but do you think you can elaborate a little more on phasing through the year? I know you mentioned kind of seasonality consistent with pre-COVID levels, but we've got a bunch of moving pieces, particularly big shifts or swings in selling days in the 2023 base period. So any more color you could provide on how you're thinking about phasing through the year? Yeah. So I think that the low point of the year would be quarter one, and then you would see improvement as you go through the remainder of the year from the revenue side, and it would be fairly consistent after quarter one. And the reason that quarter one is a little bit dampened is, as I said, there's a few tough comps in the mix there, but we would envision that once you get through to Q1, you would get back to a more normalized seasonality with quarter four, the biggest of the year, just due to the normal seasonality and patients getting more procedures done in quarter four. And this has been a phenomenon for a number of years now since Obamacare came into being. So that would be our expectation on the revenue line. Got it. Just a quick follow-up there. When you say improvement in sales each year, you think 3Q could be above 2Q in terms of sales dollars? No, I'm talking in general that once you get through the low point of Q1, that Q2, Q3, and Q4 would be above Q1, with Q4 always being the biggest quarter from a revenue perspective just due to that normal seasonality. Mike, the point I was trying to make is that Q1 would be the low point. Our next question comes from a line of Larry Biegelsen with Wells Fargo. Please go ahead. Good morning. Thanks for taking the question. Liam, what was price in 2023, and what are your expectations for 2024? I had one follow-up. Yeah, Larry, thanks for the questions. We had a good year with price in 2023. We exceeded our goal of 50 basis points and came in above that. Our goal for 2024 is to deliver another 50 basis points, and I'd be hopeful that this is the third year of the pricing cycle, so I'd be hopeful that we'd be able to at least deliver that 50 basis points again. That's helpful. So I appreciate it. I know you just guided to 2024. I appreciate your comments about the operating margin, LRP, being a bit challenging for 2025. So I guess my question is, is the 7%-10% underlying EPS growth in 2024 the right way to think about 2025? And are there any moving pieces to consider like interest expense, which I would imagine would come down from that $78 million and could be a nice tailwind for you? Any just high-level thoughts beyond 2024? Thank you. Yeah, thanks, Larry. I mean, the reason that we're calling out the underlying earnings per share is because underlying, that's what the business is doing. And therefore, we do believe that our business is well capable of driving that high single digits into the double digits. And I think even though the operating margin targets will be a challenge, I do still think that they're doable for the business. But when will we get there? If we don't get there in 2025, then get there shortly thereafter. I might ask Tom just to give a bit of color on the interest, Tom, if you don't mind. Sure. Well, just also talking about EPS and what will play well into 2025 is the fact that we've got some dilution in 2024 from the MSA going away, and that will be in the run rate by 2025. And then same thing with Palette, our expectation is that Palette turns to profitability by 2025. So those will be benefits. We're also seeing inflation coming down kind of in the marketplace, but just the way it flows through our inventory, it takes some time to clear the P&L. So if trends continue on the inflation front, we should see improving benefits by 2025 in that area. Then with regard to interest, right now, our expectation is that we will be using free cash flow in 2024 to continue to pay down some of our prepayable debt. So that will reduce our debt outstanding each quarter of the year. And then we also, in our guidance, we're assuming 3 25-basis-point rate cuts. So you should see an improving interest expense environment as we go through the year and into 2025. Our next question comes from a line of Matthew O'Brien with Piper Sandler. Please go ahead. All right. Thanks for taking the question. Just clarification upfront to make it clear for everybody on the call. 5.25 at the midpoint is the constant currency growth rate assumption. When everything's adjusted, 8.5 is the midpoint for the bottom line when everything's adjusted. I just want to make sure that's fully clear. Yeah, I think your math's good, Matt, as always. Those would be the adjusted top line and bottom line midpoints. Thank you for clarifying. That's good of you. Got it. And that's to start the year, which is what you guys tyPICCally do. Got it. So the Q1 guide actually was better than I was expecting because the comps are so tough. And I understand Palette's in there this year, but the rest of the business would have to be doing well across vascular, interventional. I don't know if there's extra selling days, but I'd just love to hear a little bit about the comfort on the outlook for Q1 specifically. And then I think it implies actually an acceleration into your stack growth over the remainder of the year. So again, I don't know if that's new products, etc., but we'd just love to hear about that. And then I do have one quick follow-up. Yeah, Matt. So our guide would assume, if I put it into percents, it would assume roughly 2%-3% for Q1 growth. Underlying would be 3.5%-4.2% normalized for the MSA and FX and the other moving pieces. As I said earlier, IUB would be a wee bit lighter just because of the tough comp. And also, you'd have the Palette ramp as you go through the year. Vascular would be a little bit lighter in the first quarter just due to the recall. And to your point, the new products ramps in particular in vascular is important this year as we go through the year. We've launched a number of new products into the PICCC franchise, and as they ramp through the year. Regarding our degree of confidence in hitting the first quarter, we're towards the back end of February, Matt, and we as a team would feel confident in our ability to deliver in that first quarter number. And as I said, we've done four for four. All of 2023, we at least reached, if not exceeded, our revenue and EPS for four quarters in a row. And as a team, we're united in the fact that we're not going to be happy until we go five for five, six for six, and ultimately eight for eight, and then reset the goal into the following year. And that's what we're planning to do. Okay. Appreciate that. And then just to Larry's question on just some of these headwinds on the EPS side that you're facing this year, I don't suspect there's a lot of upside to Palette or the MSAs this year, but it would seem like you're positioned for a meaningful snapback in terms of EPS growth next year. So just in something even in the kind of the low to mid-teens kind of EPS growth, is that am I way off base in thinking that just given all these headwinds that you're facing this year? Well, I tell you, Matt, I'd appreciate if you'd be a little bit patient with us and let us execute through 2024 before we start guiding to 2025. But we would anticipate look at I'll go back to the underlying. The underlying EPS growth, if you exclude the headwinds, is good and solid. And as Tom went through, you have a few factors that'll help then on top of that, such as Palette and interest and so on and so forth. So we'll guide to 2025 a little bit later in the year, Matt, if you don't mind. Our next question comes from a line of Mike Polark with Wolfe Research. Please go ahead. Hey, good morning. Thank you. Liam, in your prepared comment, you mentioned you're continuing to assess vertical integration opportunities to gain further control of your supply chain. I'm curious what that means. Is that an interest in doing more M&A in the OEM space, or is that just a comment on, "Hey, we're looking at any and all ways to be better on sourcing and supply chain"? So it's more the latter, Mike. What we discovered out the other side of the pandemic and as supply chain disruption hit was that if it was within our control, we were able to manage it an awful lot better than when we were reliant on third-party vendors. And there are some subcomponents that we feel we have the ability to bring in-house over time. So it's really looking at subcomponent suppliers within our supply chain. It would help our margins. That's a given as we bring it in, and that's obviously an attractive element to it as well. But it's the latter to your question. Appreciate that. The follow-up, an item in the gap-to-non-GAAP reconciliation for 2024, there's a pension charge, $2.85. It's not an insignificant number, $150 million, if I have the math correct. What's going on there? Is that a cash item, or is that a non-cash item? It's a non-cash item. So essentially, we are exiting one of our pension plans where we fully funded and offered pensioners a buyout option, and then whoever didn't take the buyout option will go and put an annuity in place for them. So essentially, we're just exiting a pension plan, but it's non-cash. Our next question comes from a line of Richard Newitter with Truist Securities. Please go ahead. Hi. It's me, Samuel Brodovsky. So not sure if I'm just wondering what assumption around organic growth you incorporated in the guide. And I also appreciate you sharing your expectation of a slight step back in OEM. How should we think about? I'm sorry. The line is incredibly bad, and we're having great difficulty hearing you. Assumption on what growth? Can you hear me now? That's a little better. Hello. Can you hear me now? Okay. That's better. So the assumption on which growth was your question? Sorry about that. Your assumption around organic growth you've incorporated in the guidance? Yes. Thank you. I apologize. We couldn't hear you that well. So the Titan Stapler, we do assume that it will grow in 2024, not at the levels we thought when we acquired it, in all transparency. We now have the impact of the GLP-1s or a good portion of the impact of the GLP-1s in our run rate as we went through 2023. And our expectation is that it will return to growth or continue to grow, I should say, in 2024. We are continuing to proctor surgeons. The product is performing exceptionally well. No issues with the Titan product itself. And now with the launch of buttress, 60% of surgeons will use buttress. Technically, our product doesn't need it, but it's how surgeons do the procedure, and therefore, having buttress will give us access to greater parts of the market. Our proctoring as recently as January was well in line with our expectations, and we continue to bring on new surgeons. Great. That's helpful. Also another one for me. You just shared your expectation of a slight step back in OEM growth. How should we think about the size of the step back? Should we consider OEM as a low double-digit grower? Thanks. Well, I think that it's going to take, I coined it as, a modest step back. So it grew around 18% or 19% last year. So it'll come back into the double-digit area as we continue to execute. So low double digits isn't a bad starting point, but just bear in mind that those modest stepbacks will be offset by step-ups in businesses like vascular, like anesthesia, and also geographically like EMEA. Our next question comes from a line of Anthony Petrone with Mizuho Securities. Please go ahead. Good morning. Thanks for piping us in and nice underlying print here. Maybe, Liam, just starting with just procedure volumes. We've been seeing a lot from the managed care companies on MLR losses, talking about procedures running hot. We've seen it across a few of the prints. I think the underlying excluding days here for Teleflex also shows that. So maybe just the state of the union on procedure volumes specific to the U.S., and then I'll have one OUS geographic question as a follow-up. Thanks. Yeah. Sure, Anthony. So what we are seeing is solid procedure volumes in the acute hospital. We continue to see that. We're back to pre-pandemic levels. I think we're executing well against it. We're also benefiting from a plethora of new product launches. And those product launches will continue into 2024 and help even augment what we're seeing from a procedural point of view within the hospital. So it's a very positive environment in the acute care hospital. And as you know, Anthony, we really like that space. No, very helpful there for the color. And then pivoting to China, we're still hearing different things about VBP, different programs that are coming out at various provincial levels. So maybe do you have any update from the Teleflex standpoint on China VBP? And more of a broader question. And I don't think this has really come up on a lot of conference calls, but everyone's so doggedly focused on VBP near-term. But should we be modeling medium-term that China is just a down-pricing market over the next three to five years, just given where things are geopolitically? Thanks. Yeah. So there are a series of provinces coming together and running volume-based procurement tenders. I think we're gone through the phase of the national tenders, and now you have amalgamations of provinces. We saw that in 2023, and we participated in some of those in 2023. While that was happening, China continued to be a real solid double-digit grower for Teleflex. So we have strategies around volume-based procurement. And I think that for Teleflex, we only sell the most unique of our products in China. We sell very, very little of our anesthesia portfolio there. We sell practically nothing of our drainage urology portfolio in China. Our main businesses there are in our coated CVCs, our interventional business, and our surgical business. There will be an impact from VBP, but because of our differentiation of our products, the discount levels are a little bit less for Teleflex, and they're being offset by volume. As you know, we had positive pricing as a company, so we're more than capable of managing what's going on within China with certain of our strategies around volume-based procurement. I'm still positive on China as a geography for Teleflex as a company, and I think that it's one that will provide growth in the longer term for the company. Our next question comes from a line of Craig Bijou with the Bank of America. Please go ahead. Thanks, guys, for taking the questions. I want to start with the high-growth product bucket. What was growth in 2023? How to think about expectations for growth in 2024 and 2025? I think Tom made a comment about investments to grow. Maybe more broadly, how do you think about your need to invest behind some of these high-growth products and considering the margin impact? Yeah. So the high-growth products portfolio performed very well in 2023. There were some really standout contributions. I'm thinking particularly of the intraosseous, the hemostatic portfolio. MANTA really continues to penetrate that market. If you look forward into the high growth for 2024, we would expect the high growth to grow in the region of 10% to 11.5%, 12%-ish, somewhere around there. We would expect the durable core to do a little bit better again this year than it did last year in the 5%-6% range. And obviously, the offset is in the other category because of the MSA, and that's going to decline in or around that 30%-ish. Regarding the investment behind it, it's easier to invest behind the high growth, Craig, in all transparency just because it has much better margins. You get the drop-through top margin from the growth even with the additional investment. Our focus of our investment has always been - and this has been for the last number of years - behind those high-growth buckets because of the margin profile and the benefit that it brings to mix within our income statement. Great. And if I can ask as a follow-up on UroLift, the office business, you highlighted that's still seeing some challenges in the U.S. What about the other sites of service in the U.S.? And then on Japan, just how do we think about the launch there and the longer-term or medium-term expectations for growth? Yeah. I'll start with Japan, then I'll talk about the sites of service. So Japan is doing exceptionally well. It's really in line with our expectations. What we told investors Japan would do, Japan is doing. The team there is executing very well. Also, geographically, we're very early in Taiwan and India, and we're ramping in those geographies. They're smaller, for sure. And we're very early days in China. We continue to work on China, getting the product listed in the public system. And the inflection point for China will be 2025 once we start to get it listed in more of the products. With regard to the sites of service, we again grew in the hospital site of service in Q4, but again, the office, unfortunately, is still challenging for us just because of the reimbursement change that was made there. Our next question comes from a line of Kristen Stewart with CL King. Please go ahead. Hi. Thanks for taking the question. The interventional business grew very nicely in this quarter and 15% for the full year on a constant currency basis. You'd mentioned MANTA was continuing to do very well there. Can you just expand upon what's driving that growth and how sustainable you feel it is going into 2024? Yeah, Kristen. So it's one of the areas that will take a modest step back. And as I said earlier, it'll be offset by the other businesses that'll take a step forward. I mean, that's why we're a portfolio company at the end of the day because you have these ebbs and flows. And they'll have a tough comp. MANTA will have a tough comp next year. It will continue to grow, but it will have that aspect. We continue to see really nice growth in the pump business. The competitor that was off the market was back in Q3. They're back in Q4, but notwithstanding that, we continue to execute well there. And the lifeblood of this business unit is new products. We have a really good cadence of new products. We launched the GuideLiner Coast last year. We've got the Ringer coming as we go through the year. Over the next number of years, we have a really nice suite of products going into the hands of this salesforce. I'm really happy with how the interventional business is going well. Obviously, the intraosseous OnControl is within there. That continues to perform very well, had a really solid quarter four as well to help drive the growth. Perfect. I just want to make sure I understand your comments around 2025 and the LRP. So it sounds like you feel pretty confident about being able to hit the gross margin line, but operating margins are going to be tougher to achieve that forecast. Is that correct? Yeah. That's what I was saying, Kristen. I mean, I think we could get there, and we have a potential path to get there. Will we get there by the end of 2025? It's tougher to get there by the end of 2025. We will get there. It just might take us a wee bit longer. And again, definitely solid path to the revenue and a solid path to the gross margin line. And underlying EPS that we've gone through with a couple of your colleagues, underlying EPS is solid. Okay. Thanks very much for the questions. Cheers, Kristen. Our final question comes from a line of Mike Matson with Needham & Company. Please go ahead. Yeah. Thanks. Just wanted to ask on Palette with Barrigel. I know, obviously, there's a big opportunity within prostate that you're going after, but I think you've talked about potential to expand into other types of cancers. So can you just talk about the timing there and whether or not you'd have to do trials to get those indications? We are expanding the indication. It is within our model. We will have to do clinical trials in order to get there. We have begun mapping out and enrolling the investigators that would help us with that. Obviously, as we build the relationship with radiation oncologists, they would be a key part of that as well as urologists in order to get this expanded indication. I don't want to go into details on the call, Mike, about what indication because, as you're very aware, in the city you live in, we have competitors. Yeah. I understand. And then just on UroLift in China, I know you've talked about the size there, and obviously, there's a ton of people there. But can you just talk about kind of the competitive landscape? And then I'm not even sure whether this is something that's covered by government payers, insurance, or is it something that's out-of-pocket for these BPH treatments there? Yeah. So the landscape is similar to where it is everywhere else insofar as that TURP is the main procedure that is used on men within China. The nuance in China is that they don't tend to be as pharma-focused insofar as that they will try other herbal remedies within that. But you're right. It's such a huge population. The way it works within China is your first step is to get it listed on all of the regional tenders. So we're going through that process now in Shanghai and Beijing. In those two big provinces, that would be an obvious place to start. And then thereafter, you apply for reimbursement. The reimbursement never covers, in any procedure, the total cost of the procedure, Mike. There's always some out-of-pocket, and the general population in China is used to have to pay out-of-pocket when they go to a hospital. Okay. Thank you. I would now like to turn the call over to Mr. Lawrence Keusch for closing remarks. Thank you, Mandeep, and thank you to everyone that joined us on the call today. This concludes the Teleflex Incorporated fourth quarter 2023 earnings conference call. That is all the time we have for questions this morning. Our conference call for today is now concluded. Thank you all for your participation.